Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (701)	9/20/1999 11:34:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 4474

you want to get sick to your stomach?....... biz.yahoo.com

To: Mike McFarland who wrote (701)	9/21/1999 1:18:00 AM
From: RWReeves	Read Replies (1) \| Respond to of 4474

Owwwww! Stop beating us Mike, we are buying all the Ariad we can afford on our meager salaries! There! another 50 shares for what would have been dinner! RWR

To: Mike McFarland who wrote (701)	9/21/1999 8:16:00 AM
From: Mike McFarland	Read Replies (1) \| Respond to of 4474

Ooops, regarding ~30M at 7/8ths...I was not thinking--the current market cap of Ariad has nothing to do with what it would cost to buy up...and I'm supposed to be hoping for an ARGENT partner anyway, not this silly talk of a buyout. Old news: The speakers at the Keystone Gene Therapy symposium in January 2000--under gene regulation, are...Ariad's Victor Rivera, and O'Malley--Baylor, and Bujard--Univ of Heidelberg. See www.Symposia.com. Dang, Ariad could take a lesson from Avigen...yet another PR from them today: biz.yahoo.com One think about Ariad--they'll never be accused of hyping, that's for sure. Okay, no more noise from me this week, too rummy on graveyards to say anything intelligible anyway:-) Goodnight!